Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Total revenues of $75 million in Q4 and $306 million for full-year 2023.
- Reaffirmed year-end cash position of $321 million and positive cash flow of $10 million for 2023.
- Initiated a shareholder approval process for a $50 million share repurchase program by the end of Q2 2024.
- Net product revenue decrease due to volume decline in VASCEPA sales in the U.S.
- Reduction in operating expenses and managing cash position to deliver $40 million of annual savings.
- Reported a net loss of $5.8 million for Q4 2023, primarily due to non-cash stock-based compensation.
- Amarin has aggregate cash and investments of $321 million as of December 31, 2023.
- 17% decrease in total net revenue for Q4 2023 compared to the same period in 2022.
- 21% decrease in net product revenue for Q4 2023 compared to the same period in 2022.
- Gross margin on net product revenue decreased to 58% in Q4 2023 from 70% in the same period of 2022.
- Reported a net loss of $5.8 million for Q4 2023 under U.S. GAAP.
- Non-GAAP adjusted net loss of $0.9 million for Q4 2023 compared to non-GAAP adjusted net income of $7.3 million in Q4 2022.
Insights
The reported decrease in total net revenue and net product revenue for Amarin Corporation plc is a significant metric for stakeholders, as it reflects a year-over-year decline of 17% and 21%, respectively. This downturn is attributed to the increased competition from generic alternatives in the U.S. market, which has led to a reduction in VASCEPA sales. The impact of such competition is a critical factor for investors, as it can signal a need for the company to innovate or diversify its product portfolio to maintain revenue streams.
Furthermore, the company's decision to initiate a share repurchase program of up to $50 million indicates a strategy to utilize excess cash to potentially enhance shareholder value and signal confidence in the company's financial health. However, this move should be assessed alongside the company's reported net loss of $5.8 million for the quarter, which contrasts with the net income reported in the previous year. The balance between returning capital to shareholders and reinvesting in the business for growth is a delicate one that requires careful scrutiny.
Amarin's operational focus on the European and Rest of World (RoW) markets, as highlighted by the President & CEO, is a strategic pivot that could open new revenue channels. This is especially important given the competitive pressures in the U.S. market. The reported European net product revenue and RoW net product revenue, although currently small, are areas to watch for potential growth. Investors should consider the company's ability to navigate different regulatory environments and market dynamics as it expands internationally.
The gross margin decline from 70% to 58% is another area of concern. It reflects not only the competitive pricing pressures but also potential inefficiencies or increased costs in the production process. The long-term sustainability of the business could be impacted if gross margins continue to compress and stakeholders should monitor whether this trend is an anomaly or indicative of a longer-term pattern.
The pharmaceutical industry is highly sensitive to patent cliffs and the introduction of generic drugs, as evidenced by Amarin's financial results. The company's focus on IPE market leadership and the mention of regulatory milestones for VASCEPA-related cardiovascular risk reduction (CVRR) submission could be pivotal. The ability to secure and maintain exclusive marketing rights or to differentiate products through clinical outcomes can be a significant driver of value. However, the reliance on a single flagship product like VASCEPA for a majority of revenue is a risk factor and diversification through R&D or strategic partnerships could be crucial for long-term stability.
Additionally, the increased licensing and royalty revenue is a positive note, suggesting that Amarin's intellectual property and regulatory achievements are generating value. This revenue stream could become more important as the company faces generic competition in its primary market.
-- Company Delivers Total Revenues of
-- Reaffirms Year-End 2023 Cash Position of
-- Company Reports Fourth Quarter 2023 Total Operating Expense of
-- Initiated Shareholder Approval Process to Execute a Share Repurchase Program of up to
-- Company to Host Conference Call Today at 8:00 a.m. EDT --
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2023 and provided an update on the Company’s operations.
“Our team is delivering operational momentum in the business. As previously announced in January, in Europe we are showing early signs of progress, particularly in Spain and the U.K.; our U.S. business is continuing its IPE market leadership; and our Rest of World (ROW) partners are advancing plans to maximize patient uptake,” said Patrick Holt, President & CEO of Amarin. “We have initiated the shareholder approval process to execute up to a
Financial Update
Total net revenue for the three months ended December 31, 2023 was
Amarin recognized licensing and royalty revenue of approximately
Cost of goods sold for the three months ended December 31, 2023 was
Selling, general and administrative expenses for the three months ended December 31, 2023 was
Research and development expenses for the three months ended December 31, 2023 were
Under U.S. GAAP, Amarin reported a net loss of
Excluding non-cash stock-based compensation expense and restructuring expense, non-GAAP adjusted net loss was
2024 Financial Outlook
Amarin continues to make progress on reducing operating expenses and managing its cash position and is on-track to deliver
Conference Call and Webcast Information
Amarin will host a conference call on February 29, 2024, at 8:00 a.m. ET to discuss this information. The conference call can be accessed on the investor relations section of the company's website at www.amarincorp.com, or via telephone by dialing 888-506-0062 within the United States, 973-528-0011 from outside the United States, and referencing conference ID 996476. A replay of the call will be made available for a period of two weeks following the conference call. To listen to a replay of the call, dial 877-481-4010 from within the United States and 919-882-2331 from outside of the United States, and reference conference ID 49775. A replay of the call will also be available through the company's website shortly after the call.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain (applying to England, Scotland and Wales). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Denmark, Finland, Austria, the UK, Spain and the Netherlands.
United States
Indications and Limitation of Use
VASCEPA is indicated:
- As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
- established cardiovascular disease or
- diabetes mellitus and two or more additional risk factors for cardiovascular disease.
- As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
- VASCEPA was associated with an increased risk (
3% vs2% ) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter. - It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
- VASCEPA was associated with an increased risk (
12% vs10% ) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin. - Common adverse reactions in the cardiovascular outcomes trial (incidence ≥
3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs3% ), peripheral edema (7% vs5% ), constipation (5% vs4% ), gout (4% vs3% ), and atrial fibrillation (5% vs4% ). - Common adverse reactions in the hypertriglyceridemia trials (incidence >
1% more frequent than placebo): arthralgia (2% vs1% ) and oropharyngeal pain (1% vs0.3% ). - Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
- Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.
FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
Europe
For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA® in Europe, please click here.
Globally, prescribing information varies; refer to the individual country product label for complete information.
Additional Information Regarding Amarin Share Repurchase Agreement
The implementation of the repurchase agreement is conditional upon shareholder and UK court approval, as required under UK company law. The Company intends to accelerate its annual general meeting of shareholders early in the second quarter of 2024 in order to seek such shareholder approval, following which it will proceed with the requisite court process to undertake a reduction of capital in order to create the necessary distributable profits for the funding of the repurchases. Amarin anticipates that these steps could be completed by the end of the second quarter of 2024, with share repurchases commencing shortly thereafter. Following receipt of the requisite approvals, Cantor will purchase such ADSs in compliance with the safe harbor provisions of Rule 10b-18 of the U.S. securities laws and the terms of the approved repurchase contract. The repurchase program will conclude at such time as Cantor has purchased
Use of Non-GAAP Adjusted Financial Information
Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the consolidated financial statements.
Non-GAAP adjusted net (loss) income was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense and restructuring expense. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations.
While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s key achievements in 2023 and the potential impact and outlook for achievements in 2024 and beyond; Amarin’s 2024 financial outlook and cash position; Amarin’s overall efforts to expand access and reimbursement to VAZKEPA across global markets; and the overall potential and future success of VASCEPA/VAZKEPA and Amarin generally. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2023. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.
Implementation of the share repurchase program is subject to shareholder and UK court approval, which may not be obtained in a timely manner or at all; Cantor may be unable to repurchase some or all of the ADSs within the parameters provided for in the share repurchase agreement; and the share repurchase may not have the expected results.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor & Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
| CONSOLIDATED BALANCE SHEET DATA | ||||||||||
| (U.S. GAAP) | ||||||||||
| Unaudited * | ||||||||||
| December 31, 2023 | December 31, 2022 | |||||||||
| (in thousands) | ||||||||||
| ASSETS | ||||||||||
| Current Assets: | ||||||||||
| Cash and cash equivalents | $ | 199,252 | $ | 217,666 | ||||||
| Restricted cash | 525 | 523 | ||||||||
| Short-term investments | 121,407 | 91,695 | ||||||||
| Accounts receivable, net | 133,563 | 130,990 | ||||||||
| Inventory | 258,616 | 228,732 | ||||||||
| Prepaid and other current assets | 11,618 | 19,492 | ||||||||
| Total current assets | 724,981 | 689,098 | ||||||||
| Property, plant and equipment, net | 114 | 874 | ||||||||
| Long-term investments | — | 1,275 | ||||||||
| Long-term inventory | 77,615 | 163,620 | ||||||||
| Operating lease right-of-use asset | 8,310 | 9,074 | ||||||||
| Other long-term assets | 1,360 | 458 | ||||||||
| Intangible asset, net | 19,304 | 21,780 | ||||||||
| TOTAL ASSETS | $ | 831,684 | $ | 886,179 | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||
| Current Liabilities: | ||||||||||
| Accounts payable | $ | 52,762 | $ | 64,602 | ||||||
| Accrued expenses and other current liabilities | 204,174 | 192,678 | ||||||||
| Current deferred revenue | 2,341 | 2,199 | ||||||||
| Total current liabilities | 259,277 | 259,479 | ||||||||
| Long-Term Liabilities: | ||||||||||
| Long-term deferred revenue | 2,509 | 13,147 | ||||||||
| Long-term operating lease liability | 8,737 | 10,015 | ||||||||
| Other long-term liabilities | 9,064 | 8,205 | ||||||||
| Total liabilities | 279,587 | 290,846 | ||||||||
| Stockholders’ Equity: | ||||||||||
| Common stock | 302,756 | 299,002 | ||||||||
| Additional paid-in capital | 1,899,456 | 1,885,352 | ||||||||
| Treasury stock | (63,752 | ) | (61,770 | ) | ||||||
| Accumulated deficit | (1,586,363 | ) | (1,527,251 | ) | ||||||
| Total stockholders’ equity | 552,097 | 595,333 | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 831,684 | $ | 886,179 | ||||||
| * Unaudited as a standalone schedule; copied from consolidated financial statements | ||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS DATA | |||||||||||||||||||
| (U.S. GAAP) | |||||||||||||||||||
| Unaudited * | |||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||
| (in thousands, except per share amounts) | (in thousands, except per share amounts) | ||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Product revenue, net | $ | 70,555 | $ | 89,507 | $ | 285,299 | $ | 366,511 | |||||||||||
| Licensing and royalty revenue | 4,158 | 738 | 21,612 | 2,682 | |||||||||||||||
| Total revenue, net | 74,713 | 90,245 | 306,911 | 369,193 | |||||||||||||||
| Less: Cost of goods sold | 29,589 | 26,641 | 102,142 | 108,631 | |||||||||||||||
| Less: Cost of goods sold - restructuring inventory | — | — | 39,228 | 18,078 | |||||||||||||||
| Gross margin | 45,124 | 63,604 | 165,541 | 242,484 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Selling, general and administrative (1) | 43,941 | 68,131 | 199,938 | 304,416 | |||||||||||||||
| Research and development (1) | 5,791 | 5,239 | 22,219 | 30,411 | |||||||||||||||
| Restructuring | 229 | (180 | ) | 10,972 | 13,526 | ||||||||||||||
| Total operating expenses | 49,961 | 73,190 | 233,129 | 348,353 | |||||||||||||||
| Operating loss | (4,837 | ) | (9,586 | ) | (67,588 | ) | (105,869 | ) | |||||||||||
| Interest income | 3,419 | 1,564 | 11,863 | 2,819 | |||||||||||||||
| Interest expense | (2 | ) | (1 | ) | (8 | ) | (15 | ) | |||||||||||
| Other (expense) income, net | (1,029 | ) | 1,250 | 2,063 | (740 | ) | |||||||||||||
| Loss from operations before taxes | (2,449 | ) | (6,773 | ) | (53,670 | ) | (103,805 | ) | |||||||||||
| (Provision for) benefit from income taxes | (3,332 | ) | 7,629 | (5,442 | ) | (1,998 | ) | ||||||||||||
| Net (loss) income | $ | (5,781 | ) | $ | 856 | $ | (59,112 | ) | $ | (105,803 | ) | ||||||||
| (Loss) earnings per share: | |||||||||||||||||||
| Basic | $ | (0.01 | ) | $ | 0.00 | $ | (0.15 | ) | $ | (0.26 | ) | ||||||||
| Diluted | $ | (0.01 | ) | $ | 0.00 | $ | (0.15 | ) | $ | (0.26 | ) | ||||||||
| Weighted average shares outstanding: | |||||||||||||||||||
| Basic | 408,485 | 399,491 | 407,655 | 401,155 | |||||||||||||||
| Diluted | 408,485 | 401,696 | 407,655 | 401,155 | |||||||||||||||
| * Unaudited as a standalone schedule; copied from consolidated financial statements | |||||||||||||||||||
| (1) Excluding non-cash stock-based compensation, selling, general and administrative expenses were 187,445 and 282,076 for 2023 and 2022, respectively, and research and development expenses were 18,032 and 25,946, respectively, for the same periods. | |||||||||||||||||||
| RECONCILIATION OF NON-GAAP NET (LOSS) INCOME | |||||||||||||||||||||
| Unaudited | |||||||||||||||||||||
| Three months ended December 31, | Year Ended December 31, | ||||||||||||||||||||
| (in thousands, except per share amounts) | (in thousands, except per share amounts) | ||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||
| Net (loss) income for EPS - GAAP | $ | (5,781 | ) | $ | 856 | $ | (59,112 | ) | $ | (105,803 | ) | ||||||||||
| Stock-based compensation expense | 4,646 | 6,612 | 16,680 | 26,805 | |||||||||||||||||
| Restructuring Inventory | — | — | 39,228 | 18,078 | |||||||||||||||||
| Restructuring expense | 229 | (180 | ) | 10,972 | 13,526 | ||||||||||||||||
| Advisor Fees | — | — | 6,270 | — | |||||||||||||||||
| Adjusted net (loss) income for EPS - non-GAAP | $ | (906 | ) | $ | 7,288 | $ | 14,038 | $ | (47,394 | ) | |||||||||||
| Basic and diluted | |||||||||||||||||||||
| (Loss) earnings per share: | |||||||||||||||||||||
| Basic - non-GAAP | $ | (0.00 | ) | $ | 0.02 | $ | 0.03 | $ | (0.12 | ) | |||||||||||
| Diluted - non-GAAP | $ | (0.00 | ) | $ | 0.02 | $ | 0.03 | $ | (0.12 | ) | |||||||||||
| Weighted average shares: | |||||||||||||||||||||
| Basic | 408,485 | 399,491 | 407,655 | 401,155 | |||||||||||||||||
| Diluted | 408,485 | 401,696 | 422,966 | 401,155 | |||||||||||||||||
FAQ
What were Amarin's total revenues for the fourth quarter of 2023?
What is Amarin's ticker symbol?
How much cash does Amarin have as of December 31, 2023?
What was the net product revenue for the three months ended December 31, 2023?
What is the focus of Amarin for 2024?
What caused the decrease in net product revenue for Q4 2023?
What was the gross margin on net product revenue for Q4 2023?
What is Amarin's 2024 financial outlook?
How can I access Amarin's conference call on February 29, 2024?
